molecules of the month


oral PMX inhibitor for malaria

50 mg QD/7 days estimated to be curative

from guanidine-based focused lib. screen. and SBDD

J. Med. Chem.

UCB Biopharma, Braine-l’Alleud, BE

UCB7362 chemical structure oral PMX inhibitor for malaria - UCB Biopharma, Braine-l’Alleud, BE
5 mins read

Context. UCB7362(UCB Biopharma) is an oral plasmepsin X (PMX) inhibitor being developed as an antimalarial agent. Malaria is a protozoan disease caused by Plasmodium sp. and remains a significant public health concern in many parts of the world, with 627,000 reported global deaths in 2020 despite the significant strides in the antimalarial drug space. Artemisin-based combination therapies (ACTs) are the standard in care for the disease, but increasing resistance to the therapy poses a significant challenge to treating and eradicating malaria. UCB7362 is a member of a novel class of compounds that target PMX, an aspartyl protease that plays a key role in P. falciparum egress. Structure-based optimization of a cyclic guanidine core, a privileged scaffold for aspartyl proteases, led…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: